Overview#
Cantor Fitzgerald has reiterated an Overweight rating for National Health Investors (NYSE:NHI) following the company's announcement of a significant portfolio sale. This decision reflects the firm’s confidence in NHI's future performance.
Portfolio Sale Details#
National Health Investors plans to sell its entire portfolio of 35 facilities to National HealthCare Corporation for $560 million. This portfolio includes approximately 4,800 beds and units, making it a substantial part of NHI's total assets, which are valued at around $4 billion. Notably, NHI has maintained consistent dividend payments for 36 years, showcasing its reliability in returning value to shareholders.
Financial Insights#
The sale is expected to yield a 7.1% lease return based on projected rents of about $40 million for 2025. However, Cantor Fitzgerald suggests that this yield is below market expectations, estimating that it could be in the mid- to high-8% range if rents increase by 25%. Currently, NHI shares are trading at $83.35, which some analyses indicate may be overvalued compared to its fair value.
Upcoming Developments#
The transaction is anticipated to close by July 1, 2026, although there is a possibility of competing offers from third parties before this date. Additionally, National Health Investors is set to report its first-quarter results for 2026 on May 4, which could provide further insights into the company's performance. Recently, NHI reported fourth-quarter earnings for 2025 that exceeded analysts’ expectations, with earnings per share of $0.80 and revenue of $105.8 million, well above projections. These positive results, along with a raised price target from Truist Securities, suggest a promising outlook for the company as it navigates market conditions.